SE0002320D0 - Malignant tumors - Google Patents
Malignant tumorsInfo
- Publication number
- SE0002320D0 SE0002320D0 SE0002320A SE0002320A SE0002320D0 SE 0002320 D0 SE0002320 D0 SE 0002320D0 SE 0002320 A SE0002320 A SE 0002320A SE 0002320 A SE0002320 A SE 0002320A SE 0002320 D0 SE0002320 D0 SE 0002320D0
- Authority
- SE
- Sweden
- Prior art keywords
- malignant tumors
- compounds
- formula
- racemate
- tautomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (27)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002320A SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Malignant tumors |
AT00973329T ATE358668T1 (de) | 1999-10-25 | 2000-10-24 | Drogen zur behandlung maligner tumoren |
CA002386775A CA2386775C (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
KR1020027005077A KR100597938B1 (ko) | 1999-10-25 | 2000-10-24 | 악성 종양의 치료용 약제 |
ES00973329T ES2280258T3 (es) | 1999-10-25 | 2000-10-24 | Farmacos para el tratamiento de tumores malignos. |
CNB008147574A CN100390148C (zh) | 1999-10-25 | 2000-10-24 | 用于治疗恶性肿瘤的药物 |
PL354540A PL199781B1 (pl) | 1999-10-25 | 2000-10-24 | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
DK00973329T DK1224172T3 (da) | 1999-10-25 | 2000-10-24 | Medikamenter til behandling af ondartede tumorer |
UA2002032524A UA73748C2 (en) | 1999-10-25 | 2000-10-24 | Medicaments for the treatment of cancer |
EEP200200207A EE200200207A (et) | 1999-10-25 | 2000-10-24 | Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid |
DE60034240T DE60034240T2 (de) | 1999-10-25 | 2000-10-24 | Drogen zur behandlung maligner tumoren |
JP2001533112A JP3950337B2 (ja) | 1999-10-25 | 2000-10-24 | 悪性腫瘍治療薬 |
AU11851/01A AU775057B2 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
NZ518296A NZ518296A (en) | 1999-10-25 | 2000-10-24 | N-phenyl-1,2-dihydro-2-oxo-quinoline-3-carboxamide derivatives and their use in the treatment of breast and prostatic cancer |
YUP-232/02A RS51019B (sr) | 1999-10-25 | 2000-10-24 | Lekovi za lečenje malignih tumora |
PCT/SE2000/002055 WO2001030758A1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
EP00973329A EP1224172B1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
KR1020067008739A KR100674160B1 (ko) | 1999-10-25 | 2000-10-24 | 악성 종양의 치료용 약제 |
IL14878200A IL148782A0 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
CZ20021293A CZ298534B6 (cs) | 1999-10-25 | 2000-10-24 | Lécivo k lécbe maligních nádoru |
HU0203238A HU229072B1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
US09/694,757 US6395750B1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumors |
IL148782A IL148782A (en) | 1999-10-25 | 2002-03-20 | Drugs for the treatment of malignant tissues |
IS6329A IS2750B (is) | 1999-10-25 | 2002-04-02 | Leiðarafesting |
HR20020353A HRP20020353A2 (en) | 1999-10-25 | 2002-04-23 | Drugs for the treatment of malignant tumours |
NO20021932A NO323320B1 (no) | 1999-10-25 | 2002-04-24 | Medikament egnet til behandling av ondartede tumorer |
HK03100644.7A HK1049830A1 (zh) | 1999-10-25 | 2003-01-24 | 用於治療惡性腫瘤的藥物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16140799P | 1999-10-25 | 1999-10-25 | |
SE9903838A SE9903838D0 (sv) | 1999-10-25 | 1999-10-25 | Novel compounds |
US21281600P | 2000-06-21 | 2000-06-21 | |
SE0002320A SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Malignant tumors |
PCT/SE2000/002055 WO2001030758A1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0002320D0 true SE0002320D0 (sv) | 2000-06-21 |
Family
ID=27484521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0002320A SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Malignant tumors |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1224172B1 (no) |
JP (1) | JP3950337B2 (no) |
KR (2) | KR100674160B1 (no) |
AT (1) | ATE358668T1 (no) |
AU (1) | AU775057B2 (no) |
CA (1) | CA2386775C (no) |
CZ (1) | CZ298534B6 (no) |
DE (1) | DE60034240T2 (no) |
DK (1) | DK1224172T3 (no) |
EE (1) | EE200200207A (no) |
ES (1) | ES2280258T3 (no) |
HK (1) | HK1049830A1 (no) |
HR (1) | HRP20020353A2 (no) |
HU (1) | HU229072B1 (no) |
IL (2) | IL148782A0 (no) |
IS (1) | IS2750B (no) |
NO (1) | NO323320B1 (no) |
NZ (1) | NZ518296A (no) |
SE (1) | SE0002320D0 (no) |
UA (1) | UA73748C2 (no) |
WO (1) | WO2001030758A1 (no) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
EP2489659B1 (en) | 2004-06-24 | 2017-12-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
CA2625287C (en) | 2005-10-19 | 2016-07-26 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
ES2790700T3 (es) | 2005-12-28 | 2020-10-28 | Vertex Pharma | Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida |
ZA200810790B (en) | 2006-06-12 | 2010-03-31 | Teva Pharma | Stable laquinimod preparations |
KR100916160B1 (ko) * | 2007-02-21 | 2009-09-08 | (주)바이오버드 | 약제학적 항암 조성물 |
EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
EP2234485B1 (en) | 2007-12-20 | 2013-11-13 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
KR20160079147A (ko) | 2008-09-03 | 2016-07-05 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 2―옥소―1,2―다이하이드로―퀴놀린 조절제 |
BRPI1011506B8 (pt) | 2009-03-20 | 2021-05-25 | Vertex Pharma | processo para a fabricação de moduladores de regulador de condutância de transmembrana de fibrose cística |
CN103153959A (zh) | 2010-10-14 | 2013-06-12 | 伊姆纳尔公司 | 作为AhR活化剂的1,2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类 |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
CN104470518A (zh) | 2012-02-27 | 2015-03-25 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
KR20150091077A (ko) * | 2012-11-07 | 2015-08-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드의 아민염 |
AU2014236232A1 (en) | 2013-03-14 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CA2961978C (en) | 2014-09-23 | 2023-03-14 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
PL3180005T3 (pl) | 2014-11-19 | 2018-06-29 | Active Biotech Ab | Chinolinokarboksyamidy do stosowania w leczeniu białaczki |
US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
IL295780A (en) | 2020-03-03 | 2022-10-01 | Active Biotech Ab | Tesquinimov or a pharmaceutically acceptable salt thereof for use in combination therapy |
EP4153576A4 (en) * | 2020-05-21 | 2024-06-19 | Stemsynergy Therapeutics Inc | NOTCH INHIBITORS AND USES THEREOF |
CA3204120A1 (en) | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
AU2022281056A1 (en) | 2021-05-25 | 2023-11-30 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
CA3221689A1 (en) | 2021-07-02 | 2023-01-05 | Hans Wannman | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
AU2022341311A1 (en) * | 2021-09-13 | 2024-03-21 | Eli Lilly And Company | Ahr agonists |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
-
2000
- 2000-06-21 SE SE0002320A patent/SE0002320D0/xx unknown
- 2000-10-24 UA UA2002032524A patent/UA73748C2/uk unknown
- 2000-10-24 CZ CZ20021293A patent/CZ298534B6/cs not_active IP Right Cessation
- 2000-10-24 ES ES00973329T patent/ES2280258T3/es not_active Expired - Lifetime
- 2000-10-24 KR KR1020067008739A patent/KR100674160B1/ko not_active IP Right Cessation
- 2000-10-24 AT AT00973329T patent/ATE358668T1/de not_active IP Right Cessation
- 2000-10-24 DK DK00973329T patent/DK1224172T3/da active
- 2000-10-24 KR KR1020027005077A patent/KR100597938B1/ko not_active IP Right Cessation
- 2000-10-24 EE EEP200200207A patent/EE200200207A/xx unknown
- 2000-10-24 AU AU11851/01A patent/AU775057B2/en not_active Ceased
- 2000-10-24 HU HU0203238A patent/HU229072B1/hu not_active IP Right Cessation
- 2000-10-24 CA CA002386775A patent/CA2386775C/en not_active Expired - Fee Related
- 2000-10-24 EP EP00973329A patent/EP1224172B1/en not_active Expired - Lifetime
- 2000-10-24 NZ NZ518296A patent/NZ518296A/xx not_active IP Right Cessation
- 2000-10-24 JP JP2001533112A patent/JP3950337B2/ja not_active Expired - Fee Related
- 2000-10-24 IL IL14878200A patent/IL148782A0/xx active IP Right Grant
- 2000-10-24 DE DE60034240T patent/DE60034240T2/de not_active Expired - Lifetime
- 2000-10-24 WO PCT/SE2000/002055 patent/WO2001030758A1/en active IP Right Grant
-
2002
- 2002-03-20 IL IL148782A patent/IL148782A/en not_active IP Right Cessation
- 2002-04-02 IS IS6329A patent/IS2750B/is unknown
- 2002-04-23 HR HR20020353A patent/HRP20020353A2/hr not_active Application Discontinuation
- 2002-04-24 NO NO20021932A patent/NO323320B1/no not_active IP Right Cessation
-
2003
- 2003-01-24 HK HK03100644.7A patent/HK1049830A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0002320D0 (sv) | Malignant tumors | |
YU23202A (sh) | Lekovi za tretman malignih tumora | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
BR0209431A (pt) | Novos compostos de 4-anilinoquinolino-3-carboxamidas | |
DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
SE9904505D0 (sv) | Novel compounds | |
PL367682A1 (en) | Dolastatin 10 derivatives | |
BR0112589A (pt) | Derivados de heteroarila e sua aplicação como medicamento | |
GB0112348D0 (en) | Compounds | |
BR0309355A (pt) | 2-(2,6-diclorofenil)-diarilimidazóis | |
SE0103836D0 (sv) | Novel compounds | |
EA200101046A1 (ru) | Производные индигоидных бис-индолов | |
SE9901875D0 (sv) | Novel compounds | |
UA83691C2 (ru) | Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона | |
DE60301339D1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
DE60001586D1 (de) | Diphenyl-piperidin derivate | |
ATE238981T1 (de) | Antitumorwirkstoffe | |
ATE424200T1 (de) | Solubilisierte topoisomerase-gift-mittel | |
MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
DE60123117D1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
CY1106576T1 (el) | Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας | |
BR0116123A (pt) | Carbazóis antitumorais | |
NO20030420L (no) | Medikament for immunoterapi av maligne tumorer | |
SE0004827D0 (sv) | Therapeutic compounds | |
WO2002098399A3 (en) | Cancer treatment method and compositions comprising compounds of the ginger family |